Browse articles from EyeWorld.org related to dry eye. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
While this bonus issue delves into the diverse aspects of dry eye, the EyeWorld Editorial Board thought it was important to call out dry eye masqueraders—conditions that might initially seem like dry eye but aren’t. EyeWorld spoke with one physician to gain insights on these dry eye decoys.
With an increase in dry eye education and treatment options, questions can arise: Who really needs surface optimization vs. who is ready to schedule surgery now? What’s reasonable in terms of treatment? When is a patient who needed ocular surface optimization ready for surgery? Two experts shared their experiences.
The president and CEO of the Sjögren’s Foundation as well as two ophthalmologists spoke about the diagnosis journey, available treatments, and future hopes for patients with Sjögren’s disease.
➤ FDA approves aceclidine-based drop for presbyopia ➤ Long-term data supports efficacy of continuous wet AMD treatment ➤ First patient dosed in trial for drug eluting lacrimal canaliculus plug ➤ Acquisition news ➤ ASCRS news and events
➤ Phase 3 results for preservative-free redness reliever ➤ Enrollment complete in Phase 3 pivotal program for wet AMD treatment ➤ Dry AMD Phase 3 trial completes enrollment ➤ Study: 24-month data confirm durability of dry eye procedural treatment ➤ Partnership and acquisition news ➤ ASCRS news and events
➤ Topline Phase 2 results for drug treating neuropathic corneal pain ➤ Phase 3 blepharitis treatment doesn’t meet primary endpoint ➤ Study: therapeutic potential of collagen mimetic peptides for myopia ➤ FDA accepts NDA resubmission for dry eye therapy ➤ Partnership news ➤ ASCRS news and events
With dry eye presenting as an increasingly common issue, many companies are exploring options to treat these patients. New products in development are seeking to address different aspects of dry eye, with various amechanisms of action. Three specialists discussed some of these.
➤ Initial Phase 3 results for dry eye disease therapy ➤ Positive Phase 2 results for intravitreal implant for glaucoma and diabetic retinopathy ➤ Phase 1/2a results from allogenic cell therapy for geographic atrophy ➤ Phase 1 trial successful with oral treatment for non-proliferative diabetic retinopathy ➤ ASCRS news and events
➤ Preservative-free fixed-dose combination therapy for glaucoma in development ➤ Rare Pediatric Disease designation granted to investigational Stargardt gene therapy ➤ First patient dosed in genome editing program for corneal dystrophy ➤ ASCRS news and events
➤ FDA approves first-in-class DED drop ➤ FDA accepts NDA for topical presbyopia therapy ➤ TFOS DEWS III ➤ Topline results in Phase 3 study evaluating night driving impairment after keratorefractive surgery ➤ IND application submitted for pediatric myopia treatment ➤ Study sheds light on clinical inherited retinal diseases without genetic mutations ➤ ASCRS news and events